This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2024
ASCO GU 2024
Prostate Cancer
Bladder Cancer
Kidney Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Upper Tract Urothelial Carcinoma
Press Releases
ASCO GU 2024 Bladder Cancer
Viewing 21-40 of 53 articles
ASCO GU 2024: AMBASSADOR Alliance A031501: Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma Versus Observation (Late-Breaking Abstract)
ASCO GU 2024: Predicting Clinical Outcomes in the S1314-COXEN Trial Using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression
ASCO GU 2024: Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma (PemCab)
ASCO GU 2024: Avelumab First-Line Maintenance Therapy for Locally Advanced/metastatic Urothelial Carcinoma: Results from the Real-World US PATRIOT-II Study
ASCO GU 2024: GDFather-Neo - Neutralizing GDF-15 in MIBC: A Neoadjuvant Immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab
ASCO GU 2024: Enfortumab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma: Subgroup Analyses Results from EV-302, a Phase 3 Global Study
ASCO GU 2024: INVEST: A Phase Ib Window of Opportunity Study of Atezolizumab Administered Either Intravesically or Direct Tumor Injection in Patients with Bladder Cancer Prior to Radical Cystectomy
ASCO GU 2024: First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Followed by Postsurgical Adjuvant Nivolumab in Patients with MIBC
ASCO GU 2024: Sequencing of Erdafitinib and Enfortumab Vedotin in Patients with FGFR2/3 Altered Advanced Urothelial Cancer: Analysis of UNITE Database
ASCO GU 2024: Interim Analysis of a Phase I/Ib Study of Enfortumab Vedotin plus Cabozantinib in Patients with Metastatic Urothelial Carcinoma
ASCO GU 2024: BladderGATE: Atezolizumab + intravesical BCG Upfront Combination in Patients with High-risk NMIBC—Phase I-II ONCOSUR Study
ASCO GU 2024: A Phase 1 Study of IO102-IO103 Vaccine Plus Pembrolizumab in Patients with BCG-intolerant or Unresponsive Non-Muscle Invasive Bladder Cancer
ASCO GU 2024: Pembrolizumab with Favezelimab or Vibostolimab for Patients with BCG–unresponsive High-risk Non–muscle-Invasive Bladder Cancer: Phase 2 KEYNOTE-057 Cohort C
ASCO GU 2024: PIVOT-006: A phase 3, Randomized Study of Cretostimogene Grenadenorepvec vs Observation for the Treatment of Intermediate Risk Non-muscle Invasive Bladder Cancer Following TURBT
ASCO GU 2024: Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer in China: An Analysis of Unpublished Clinical Trial and Real-World Data
ASCO GU 2024: BCG Shortage: What’s on the Horizon to Replace?
ASCO GU 2024: Punch: Preliminary Results from a Phase II Study of Intra‑arterial Chemotherapy Combined with Tislelizumab and BCG in High-Risk Non-Muscle-Invasive Bladder Cancer
ASCO GU 2024: SAKK 06/19 - Intravesical Recombinant BCG Followed by Perioperative Chemo-Immunotherapy for Patients with Muscle-Invasive Bladder Cancer: A Multicenter, Single Arm Phase 2 Trial
ASCO GU 2024: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer
ASCO GU 2024: Adverse Effects and Discontinuation of Pembrolizumab in BCG Refractory Non-Muscle Invasive Bladder Cancer
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free